It has been a little disappointing the follow through this week given the big M&A. It is not a disaster of a response but certainly not as good as I was expecting. We still have one day left so perhaps today can get us to new highs. There has not been a lot of news […]
December 17th Biotech Update
I am a little surprised at the lack of follow through after Monday. I expected the potential of a small retracement but then strength to return to the sector. I am not willing to say the trading is indicating a near term top is in for the sector as we are still in a seasonally […]
December 16th Biotech Update
Well, we have had two red days in a row after Monday’s move. I noted that we should be setup for a rally into the end of the year and that anything other than that bodes poorly in the near term. So is it time to call it and in the short term? Not quite […]
December 14th Biotech Update
We should certainly see all time highs this week to continue. We are in a seasonally good period and the news is certainly supportive. If we are unable to run off of this news it sends a strong signal. Certainly we were already at highs but this news should bring even more buyers into the […]
APLIF – Appili Therapeutics and Avigan, the Antiviral Pill to treat Coronavirus: The Clinical Strategy for EUA
Canada TSX: APLI, US OTCQX: APLIF We previously reported on the need for COVID-19 therapeutics, including in the post-vaccine world, Appili Therapeutics and Avigan the Antiviral Pill to Treat Coronavirus (link here). Since the publication of that report, daily infections have only continued to rise, and nursing facilities and hospitals are facing an intensified crisis. […]
December 10th Biotech Update
The sector is clearly doing well and there is some interesting news that perhaps bodes well heading into JPM and the end of the year. We are not quite making news highs again today but the sector is feeling like it wants to and it really stands in stark contrast to the pandemic and economy. […]
December 9th Biotech Update
The sector has not had the typical post-conference weakness, which is good to see. Also, there have been a good set of secondaries with the sector still being strong. It is not strange to see secondaries pop up during strong moves as that is pretty typical. What is interesting is that we usually see these […]
December 7th Biotech Update
So far we do not have an ASH selloff, which is nice to see. I think in general we remain with some seasonal and broader market tailwinds and that should take us through JPM in January. In fact, we are probably getting close to the M&A speculation time but remember that last year was actually […]
December 3rd Biotech (and MLP) Update
Sorry for the delay but we are dealing with kids that were exposed to COVID and having to get them tested and now they are back in virtual school. I am sure many of you have dealt with similar (or worse) issues and thankfully for us it is just added time but it certainly has […]
December 1st Biotech Update
A strong start to the week that is continuing. While certain sentiment measures are getting into danger territory, it still seems like the market has a little bit more room for running. The uncertainty around the elections is waning and the Biden economic team seems to indicate a strong desire for fiscal stimulus. We are […]
November 30th Biotech Update
As I have said there will be a tug of war in the market and so far vaccine hopes and seasonality are winning over the growing pandemic. One really has to worry about an out of control pandemic combined with a holiday season but the market is not quite ready to worry about it. I […]
November 23 Biotech Update
The market dynamics remain the same. We are entering what tends to be a seasonally positive period of the year, which might add some tailwind to the broader market. While I still think the market is going to focus on the prospects of the vaccine coming next year as opposed to the out of control […]
APLIF – Appili Therapeutics and Avigan the Antiviral Pill to Treat Coronavirus
Canada TSX: APLI, US OTC: APLIF Recent vaccine news from Pfizer (PFE) and Moderna (MRNA) provide some optimism to a world suffering from disease, death, and lockdown, and desperately looking for a solution to the COVID-19 pandemic for a return to normal life and work. Safe and effective vaccines will help contain the spread of […]
November 20th Biotech Update
I think choppy might have been the best description of the market at this point. This makes sense give the competing influences on both the market and economy. I would not be surprised to see this chop continue or perhaps even see some consolidation. The broader market seems in a little more precarious position than […]
November 19th Biotech Update
Nothing crazy happening in the market at this point. I do not see anything that compelling low or high and I think the market continues to struggle with the hope of the vaccines versus the pain of an out of control spread. There is likely a point where the immediate term gets so bad that […]
November 18th Biotech (and MLP) Update
So the market continues to look good including the sector that is pushing all time highs. While I often say the trend is your friend (and it is), it might also be time to pull out another saying. When markets are making all time highs, the most likely outcome is to continue to make marginal […]
Pluristem- Expectation Ahead of CLI Phase-3 Interim Results
These are the questions that many are asking me these days regarding PSTI: * When will the interim Ph3 data be released? * What is taking them so long? * Is there a chance they are withholding the data because it is negative, and they will wait until full study data is available to provide […]
November 16th Biotech Update
Another start to the week with some more vaccine announcements (positive). It was good to see more positive vaccine data but it does not change the dynamic that I see with the market. There appears to be a real light at the end of the tunnel but the path to the end will be very […]
November 13th Biotech Update
So its been a decent week and hopefully we can end on a strong note. Not a lot of news to move the market or sector and perhaps that means we get a decent look at the underlying sentiment of the market. We are past the major catalysts of November and there is really not […]
November 12th Biotech Update
The market continues to move along it sort of the honeymoon period post election risk reduction. I still worry about the pandemic as cases continue to grow unabated in the EU and US. Is it possible that the market (and Americans) simply do not care about it anymore and have simply accepted the death as […]
